The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)
Abstract
Purpose: In experimental systems, interference with coagulation can affect tumor biology. Furthermore, it has been suggested that low molecular weight heparin therapy may prolong survival in patients with cancer. The primary aim of this study was to assess survival at 1 year of patients with advanced cancer. Patients and Methods: Patients with advanced malignancy (N = 385) were randomly assigned to receive either a once-daily subcutaneous injection of dalteparin (5,000 IU), a low molecular weight heparin, or placebo for 1 year. Results: The Kaplan-Meier survival estimates at 1, 2, and 3 years after randomization for patients receiving dalteparin were 46%, 27%, and 21%, respectively, compared with 41%, 18%, and 12%, respectively, for patients receiving placebo (P = .19). In an analysis not specified a priori, survival was examined in a subgroup of patients (dalteparin, n = 55; and placebo, n = 47) who had a better prognosis and who were alive 17 months after randomization. In these patients, Kaplan-Meier survival estimates at 2 and 3 years from randomization were significantly improved for patients receiving dalteparin versus placebo (78% v 55% and 60% v 36%, respectively, P = .03). The rates of symptomatic venous thromboembolism were 2.4% and 3.3% for dalteparin and placebo, respectively, with bleeding rates of 4.7% and 2.7%, respectively. Conclusion: Dalteparin administration did not significantly improve 1-year survival rates in patients with advanced malignancy. However, the observed improved survival in a subgroup of patients with a better prognosis suggests a potential modifying effect of dalteparin on tumor biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (2001) · Chest · doi:10.1378/chest.119.1_suppl.64s · Cited by 1,580
Hirsh, J., & Levine, M. (1992) · Blood · doi:10.1182/blood.v79.1.1.bloodjournal7911 · Cited by 894
Self-citationHeparin and heparan sulfate: Structure and function
Rabenstein, D. L. (2002) · Natural Product Reports · doi:10.1039/b100916h · Cited by 870
Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M., & Varki, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061615598 · Cited by 714
Mismetti, P., Laporte, S., Darmon, J.-Y., Buchmüller, A., & Decousus, H. (2001) · Journal of British Surgery · doi:10.1046/j.0007-1323.2001.01800.x · Cited by 649
Gould, M. K., Dembitzer, A. D., Doyle, R. L., Hastie, T. J., & Garber, A. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-10-199905180-00003 · Cited by 627
Managing Oral Anticoagulant Therapy
Ansell, J., Hirsh, J., Dalen, J., Bussey, H., Anderson, D., Poller, L., Jacobson, A., Deykin, D., & Matchar, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.22s · Cited by 572
Levine, M., Hirsh, J., Arnold, A., Gent, M., Levine, M., Arnold, A., Bramwell, V., Pritchard, K. I., Stewart, D., Warr, D., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90008-6 · Cited by 510
Self-citationSiragusa, S., Cosmi, B., Piovella, F., Hirsh, J., & Ginsberg, J. S. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)89484-3 · Cited by 373
Zacharski, L. R., Henderson, W. G., Rickles, F. R., Forman, W. B., Cornell, C. J., Forcier, A. J., Edwards, R. L., Headley, E., Kim, S.-H., O'Donnell, J. F., et al. (1984) · Cancer · doi:10.1002/1097-0142(19840515)53:10<2046::aid-cncr2820531007>3.0.co;2-f · Cited by 343
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers
Chew, H. K., Wun, T., Harvey, D. J., Zhou, H., & White, R. H. R. (2006) · Archives of Internal Medicine · doi:10.1001/.458 · Cited by 1,321
Palumbo, J. S., Talmage, K. E., Massari, J. V., La Jeunesse, C. M., Flick, M. J., Kombrinck, K. W., Jirousková, M., & Degen, J. L. (2005) · Blood · doi:10.1182/blood-2004-06-2272 · Cited by 999
Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N. M., Levine, M. N., Liebman, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1283 · Cited by 952
Self-citationLyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Italiano, J. E., Richardson, J. L., Patel-Hett, S., Battinelli, E., Zaslavsky, A., Short, S., Ryeom, S., Folkman, J., & Klement, G. L. (2008) · Blood · doi:10.1182/blood-2007-09-113837 · Cited by 859
Trousseau's syndrome: multiple definitions and multiple mechanisms
Varki, A. (2007) · Blood · doi:10.1182/blood-2006-10-053736 · Cited by 840
The Platelet Lifeline to Cancer: Challenges and Opportunities
Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V., & Sood, A. K. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.002 · Cited by 638
Agnelli, G., Gussoni, G., Bianchini, C., Verso, M., Mandalà, M., Cavanna, L., Barni, S., Labianca, R., Buzzi, F., Scambia, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70232-3 · Cited by 598
Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial
McBane, R. D., Wysokinski, W. E., Le‐Rademacher, J. G., Zemla, T., Ashrani, A., Tafur, A., Perepu, U., Anderson, D., Gundabolu, K., Kuzma, C., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14662 · Cited by 591
Cancer and venous thromboembolism
Prandoni, P., Falanga, A., & Piccioli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70207-2 · Cited by 540
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis
Ilan, N., Elkin, M., & Vlodavsky, I. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.06.004 · Cited by 524
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines
Mandalà, M., Falanga, A., & Roila, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr392 · Cited by 512
Nierodzik, M. L., & Karpatkin, S. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.002 · Cited by 502
Labelle, M., & Hynes, R. O. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0329 · Cited by 486
Sialic acids in cancer biology and immunity
Pearce, O. M. T., & Läubli, H. (2016) · Glycobiology · doi:10.1093/glycob/cwv097 · Cited by 470
Lee, A. Y. Y., Rickles, F. R., Julian, J. A., Gent, M., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., & Levine, M. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.133 · Cited by 453
Self-citationAy, C., Simanek, R., Vormittag, R., Dunkler, D., Alguel, G., Koder, S., Kornek, G., Marosi, C., Wagner, O., Zielinski, C., et al. (2008) · Blood · doi:10.1182/blood-2008-02-142422 · Cited by 422
Deadly allies: the fatal interplay between platelets and metastasizing cancer cells
Erpenbeck, L., & Schön, M. P. (2010) · Blood · doi:10.1182/blood-2009-10-247296 · Cited by 345
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
Maraveyas, A., Waters, J., Roy, R., Fyfe, D., Propper, D., Lofts, F., Sgouros, J., Gardiner, E., Wedgwood, K., Ettelaie, C., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.017 · Cited by 316
Heparan Sulfate: Biosynthesis, Structure, and Function
(2016) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.02.009 · Cited by 298
Incidence of Venous Thromboembolism and the Impact on Survival in Breast Cancer Patients
Chew, H. K., Wun, T., Harvey, D. J., Zhou, H., & White, R. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4393 · Cited by 278
López, J. A., Kearon, C., & Lee, A. Y. Y. (2004) · Hematology · doi:10.1182/asheducation-2004.1.439 · Cited by 272
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Di Nisio, M., Porreca, E., Ferrante, N., Otten, H.-M., Cuccurullo, F., & Rutjes, A. W. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008500.pub2 · Cited by 264
Therapeutic value of glycosaminoglycans in cancer
Yip, G. W., Smollich, M., & Götte, M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0082 · Cited by 263
Guidelines on the use and monitoring of heparin
Baglin, T., Barrowcliffe, T. W., Cohen, A., Greaves, M., & the British Committee for Standards in Haematology (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05953.x · Cited by 262
Young, A., Chapman, O., Connor, C., Poole, C., Rose, P., & Kakkar, A. K. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.106 · Cited by 150
Self-citationMechanisms and management of thrombosis in cancer: Focus on gastrointestinal malignancies
Monegatti, S., Martinelli, N., Friso, S., Spronk, H. M. H., & Cate, H. T. (2025) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002203 · Cited by 10
Metadata
- Authors
- Kakkar, A. K., Levine, M. N., Kadziola, Z., Lemoine, N. R., Low, V., Patel, H. K., Rustin, G., Thomas, M., Quigley, M., & Williamson, R. C. N.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-05-15
- Volume
- 22
- Issue
- 10
- Pages
- 1944-1948
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142386661
- Cited by
- 650
- References
- 19
- FWCI
- 34.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.